Evidence map›Paper›PMID 41996414›Full record

ArticlePloS one2026

A novel SLC20A2 nonsense variant and mechanistic studies of primary brain calcification.

Yi Li, Lamei Yuan, Han Chen, Wen Zheng, Hongbo Xu, Zhijian Yang, Dan He, Hao Deng

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yi LiDepartment of Laboratory Medicine, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lamei YuanResearch Center of Medical Experimental Technology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Han ChenDepartment of Neurology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wen ZhengDepartment of Neurology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hongbo XuCenter for Experimental Medicine, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhijian YangCenter for Experimental Medicine, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Dan HeDepartment of Pathology, Hunan Aerospace Hospital, Changsha, Hunan, China.
Hao DengDepartment of Laboratory Medicine, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID https://orcid.org/0000-0003-3240-4352

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary brain calcification (PBC) is a rare neurodegenerative disease featured by bilateral brain calcifications and exhibiting high phenotypic and genetic heterogeneity. The clinical manifestations mainly include movement disorders, cognitive deficits, and neuropsychiatric symptoms. In this study, a novel heterozygous nonsense variant, c.1669C > T [p.(Gln557*)], in the solute carrier family 20 member 2 gene (SLC20A2), encoding type III sodium-dependent inorganic phosphate transporter 2 (PiT2), was identified in a Han-Chinese family with PBC using whole exome sequencing and Sanger sequencing. Bioinformatics analysis predicted the variant's deleterious effect. The cellular function impacts of the p.Gln557* variant and three other common PBC-related SLC20A2 variants, p.Ser113*, p.Ala585Thr, and p.Ser601Trp, were subsequently revealed. Subcellular localization analysis showed that the PiT2-Q557*, A585T, and S601W mutants mainly distributed in the plasma membrane and cytosol, whereas the PiT2-S113* mutant showed a diffuse distribution throughout the cells. All four investigated variants significantly impaired cellular inorganic phosphate transport activity. The protein mislocalization-inducing p.Ser113* variant likely causes haploinsufficiency, while the p.Gln557*, p.Ala585Thr, and p.Ser601Trp variants may lead to full or partial loss of function, or exert a dominant-negative effect. Cells expressing PiT2 mutants all exhibited inhibited proliferative and migratory activities, along with enhanced apoptosis. These SLC20A2 variants probably impair critical cellular functions, potentially providing an explanation for the neurological symptoms observed in PBC patients. These findings further broaden SLC20A2 variant spectrum and provide valuable mechanistic insights into the pathogenesis of SLC20A2-associated PBC.

Indexed as

BrainBrain DiseasesCalcinosisCodon, NonsenseSodium-Phosphate Cotransporter Proteins, Type IIIFemaleHumansMalePedigreeCodon, NonsenseSLC20A2 protein, humanSodium-Phosphate Cotransporter Proteins, Type III

Identifiers

PMID41996414
PMCPMC13089887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.